VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. O'Neil Discusses the Development of Biomarkers for CRC

Bert O’Neil, MD
Published: Friday, Aug 11, 2017



Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the development of biomarkers for colorectal cancer (CRC).

It is too early to state whether a biomarker will matter for combinations for the treatment of patients with CRC, explains O’Neil. Phase III data are needed to further investigate that question, but trials can be difficult to get started.



Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the development of biomarkers for colorectal cancer (CRC).

It is too early to state whether a biomarker will matter for combinations for the treatment of patients with CRC, explains O’Neil. Phase III data are needed to further investigate that question, but trials can be difficult to get started.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x